Please assess the completion status of the following clinical trial:

Trial Title: CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* IRSS stage II or stage IIIa RB patients.~* for patients with IRSS stage II disease, if scleral surface invasion alone was observed, only systemic chemotherapy was administered, whereas other IRSS stage II and IIIa patients received systemic chemotherapy plus additional local chemotherapy.~* no tumor-related treatment was given prior to this chemotherapy regimen.~Exclusion Criteria:~* metastasis, including lymph node metastasis.~* the diagnosis of IRSS stage I or above in the non-target eye.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CEV with/without carboplatin (Type: EXPERIMENTAL): CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).